Unicycive Therapeutics, Inc.
UNCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001766140
No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $54.6M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Unicycive Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +3 vs. Q1 2022
- Shares held
- 1.19M
- +43.9K (+3.8%) vs. Q1 2022
- Total value
- $992.0K
- −$483.0K (−32.7%) vs. Q1 2022
- New holders
- 5
- 3 more added
- Sold out
- 2
- 1 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting UNCY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 79 | $54.6M |
| Q1 2026 | 51 | $65.2M |
| Q4 2025 | 35 | $47.5M |
| Q3 2025 | 30 | $27.4M |
| Q2 2025 | 20 | $24.6M |
| Q1 2025 | 29 | $34.5M |
| Q4 2024 | 31 | $49.0M |
| Q3 2024 | 29 | $19.1M |
| Q2 2024 | 24 | $9.52M |
| Q1 2024 | 23 | $31.6M |
| Q4 2023 | 16 | $11.3M |
| Q3 2023 | 16 | $12.2M |
| Q2 2023 | 15 | $1.38M |
| Q1 2023 | 13 | $3.54M |
| Q4 2022 | 9 | $428.3K |
| Q3 2022 | 12 | $571.0K |
| Q2 2022 | 15 | $992.0K |
| Q1 2022 | 12 | $1.48M |
| Q4 2021 | 12 | $2.30M |
| Q3 2021 | 10 | $3.02M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Unicycive Therapeutics, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 729,680 | $606.0K | 0.05% | +89,047+13.9% | Added |
| Board of Trustees of The Leland Stanford Junior University | 247,583 | $205.0K | 0.01% | 00.0% | Unchanged |
| Ayrton Capital LLC | 76,645 | $64.0K | 0.10% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 26,109 | $21.0K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 22,695 | $19.0K | 0.00% | 00.0% | Unchanged |
| Frontier Wealth Management LLC | 18,800 | $16.0K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 15,210 | $13.0K | 0.00% | −21,986−59.1% | Reduced |
| Tandem Capital Management Corp | 15,500 | $13.0K | 0.01% | 00.0% | Unchanged |
| FineMark National Bank & Trust | 15,625 | $13.0K | 0.00% | +15,625 | New |
| Renaissance Technologies LLC | 11,000 | $9.00K | 0.00% | +11,000 | New |
| Tower Research Capital LLC (TRC) | 5,167 | $4.00K | 0.00% | +1,326+34.5% | Added |
| Royal Bank of Canada | 5,000 | $4.00K | 0.00% | +5,000 | New |
| UBS Group AG | 4,491 | $4.00K | 0.00% | +4,491 | New |
| Spire Wealth Management | 1,000 | $1.00K | 0.00% | +1,000 | New |
| Wells Fargo & Company | 36 | $0 | 0.00% | +3+9.1% | Added |
| Truist Financial Corp | 0 | $0 | 0.00% | −37,462−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −24,166−100.0% | Sold out |